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Abstract
Delirium is one of the foremost unmet medical needs in healthcare. It affects one in eight hospitalised patients and is asso-
ciated with multiple adverse outcomes including increased length of stay, new institutionalisation, and considerable patient dis-
tress. Recent studies also show that delirium strongly predicts future new-onset dementia, as well as accelerating existing
dementia. The importance of delirium is now increasingly being recognised, with a growing research base, new professional
international organisations, increased interest from policymakers, and greater prominence of delirium in educational and audit
programmes. Nevertheless, the ﬁeld faces several complex research and clinical challenges. In this article we focus on selected
areas of recent progress and/or uncertainty in delirium research and practice. (i) Pathogenesis: recent studies in animal models
using peripheral inﬂammatory stimuli have begun to suggest mechanisms underlying the delirium syndrome as well as its link
with dementia. A growing body of blood and cerebrospinal ﬂuid studies in humans have implicated inﬂammatory and stress
mediators. (ii) Prevention: delirium prevention is effective in the context of research studies, but there are several unresolved
issues, including what components should be included, the role of prophylactic drugs, and the overlap with general best care for
hospitalised older people. (iii) Assessment: though there are several instruments for delirium screening and assessment, detection
rates remain dismal. There are no clear solutions but routine screening embedded into clinical practice, and the development of
new rapid screening instruments, offer potential. (iv) Management: studies are difﬁcult given the heterogeneity of delirium and
currently expert and comprehensive clinical care remains the main recommendation. Future studies may address the role of drugs
for speciﬁc elements of delirium. In summary, though facing many challenges, the ﬁeld continues to make progress, with several
promising lines of enquiry and an expanding base of interest among researchers, clinicians and policymakers.
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Introduction
Over a decade ago, the editors of the book ‘Delirium in Old
Age’ [1] stated their concerns about waning interest in delir-
ium. They remarked that in 1970, the word ‘delirium’ was
referenced in 2.5% (n= 203) of all Medline articles mentioning
‘patient’ or ‘subject’. By 2000, this had fallen to 0.2% (n= 253).
In 2013 this proportion is the same, and so delirium remains
massively understudied in relation to its status as a major cause
of ill-health. Nevertheless, the last 5 years has seen much novel
research in basic and clinical pathogenesis, neuropsychology
and delirium as a predictor of long-term cognitive decline. In
parallel with the growing research base, delirium is gaining a
higher proﬁle among healthcare professionals. Publication of
the UK NICE guidelines [2] in 2010 was a key step forward,
and crucially the 2012–13 National Audit of Dementia Care in
667
Age and Ageing 2013; 42: 667–674
doi: 10.1093/ageing/aft148
© The Author 2013. Published by Oxford University Press on behalf of the British Geriatrics Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Published electronically 25 September 2013
Acute Hospitals highlighted delirium detection and manage-
ment as an essential part of good dementia care [3]. Funders
and policymakers are also increasingly recognising delirium in
the form of targeted grant calls and statements urging that delir-
ium be included in educational programmes, audits and external
quality inspections. Two ﬂourishing international professional
organisations dedicated to delirium research and practice have
been established: the European Delirium Association and the
American Delirium Society; both host successful annual meet-
ings. Thus the ﬁeld is clearly expanding on several fronts as
awareness of delirium’s enormous impact becomes more widely
known. Yet despite these advances, large scale improvements to
its clinical care are yet to materialise, and delirium remains
almost invisible to the general public.
In this article, we focus on delirium in hospitalised older
people. Our goal is not to provide a comprehensive overview but
rather to highlight selected areas in which there has been recent
progress or that show substantial promise for development.
Pathogenesis
Delirium is a heterogeneous and ﬂuctuating syndrome result-
ing mostly from peripheral conditions that precipitate acute
brain dysfunction. It is now evident that delirium is also asso-
ciated with brain injury, because delirium is a strong risk factor
for new onset dementia [4] as well as acceleration of existing de-
mentia [5]. Thus, there are several overlapping domains of
enquiry. These include understanding how peripheral infections
elicit brain dysfunction, the dysfunction causing delirium itself
and the processes underpinning the association of delirium with
long-term cognitive decline. Given the complexity of the brain
and its interactions with the periphery, numerous processes are
likely involved. Yet in some cases the causation of delirium and
associated brain injury is not difﬁcult to understand, at least con-
ceptually. Delirium commonly results from speciﬁc, readily de-
ﬁnable insults such as hypoxia, metabolic abnormalities, stroke
and drug effects. This broad category of precipitants can be
termed ‘direct brain insults’ [6]. In many other cases patients
with delirium have not had a signiﬁcant direct brain insult, for
example, where the cause of delirium is an apparently mild per-
ipheral infection or injury that has not led to substantial physio-
logical disturbance. In these situations, it can be assumed that
the delirium has been initiated by aspects of the body’s response
to the insult. We have termed this second category of causes of
delirium ‘aberrant stress responses’. Here, ‘stress’ broadly refers
to the sympathetic nervous system, hypothalamic–pituitary–
adrenal axis, inﬂammatory pathways and other systems activated
in response to acute threat. The term ‘aberrant’ is used because
the stress response may be exaggerated and manifestly has
adverse effects on the brain.
Human studies
In humans, exogenous administration of peripheral pro-
inﬂammatory cytokines is known to cause cognitive dysfunction,
and even delirium, mediated at least partly by altered
neurotransmission. Direct evidence linking inﬂammatory
cytokines and cortisol with delirium comes from studies of
blood [7, 8] and cerebrospinal ﬂuid (CSF) [9]. Elevated en-
dogenous levels of serum interleukin (IL)-6 and IL-8 have
been found in elderly hospital inpatients who develop delir-
ium, even after correcting for infection and baseline cognitive
impairment [10], with similar ﬁndings in hip fracture patients
[11]. Levels of IFN- (pro-inﬂammatory), IL-RA and IGF-1
(anti-inﬂammatory) are altered in delirium [12, 13]. CSF IL-8
is increased [14]. An exaggerated stress response to acute
illness, often combined with impaired negative feedback,
results in high cortisol. This is commonly seen with ageing
and neurodegenerative disease [6]. Elevated cortisol is an
established cause of mental status deterioration and one
prominent hypothesis of delirium pathogenesis is that delir-
ium is precipitated by pathologically elevated cortisol occur-
ring with acute stress from illness or surgery [6]. Several
studies have investigated this proposition possibility, in
serum samples [15], and CSF [16].
How direct brain insults and aberrant stress responses lead
to the brain dysfunction underlying delirium is not well under-
stood, though the association of certain classes of drugs with de-
lirium has implicated cholinergic, dopaminergic, adrenergic and
GABAergic systems. Evidence of increased dopaminergic sig-
nalling has been found in the CSF of delirium patients with
psychotic features [17]. Further CSF and functional neuroima-
ging experiments are required to identify abnormalities in neuro-
transmission occurring during delirium in humans; animal studies
will be useful in suggesting lines of enquiry (see below).
The mechanisms underlying the association between delirium
and dementia are under-researched in humans. Post-mortem
studies have raised the intriguing possibility that the pro-
cesses linking delirium and dementia may not be mediated
by classical dementia pathology [4]; it is likely that inﬂamma-
tory pathways are important given the evidence from animal
studies [18]. Elevated CSF levels of S100B, a marker of CNS
damage derived largely from astrocytes, were reported in
active delirium in patients with hip fracture compared with
those without delirium [19]. This is consistent with similar
ﬁndings in blood [20]. Clearly, this is a domain of delirium
research that is of great interest given the implications for
primary and secondary prevention of dementia.
Animal studies
Animal models offer enormous potential in delirium patho-
physiological research. Of all the mental disorders delirium is
particularly amenable to animal studies, because it is acute,
severe and measurable, and because clinical studies have pro-
vided clear leads on precipitants and factors increasing vul-
nerability. For example, animal studies are able to directly test
the hypotheses, frequently suggested in clinical review arti-
cles, that peripheral inﬂammation induces or synergises with
central cholinergic dysfunction to induce transient behav-
ioural change resembling delirium. More sophisticated
studies involving combinations of aetiological factors are also
possible and these could more closely model the
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complexities seen in clinical practice. Animal studies can also
discover new biomarkers, and identify and test candidate
drug treatments.
The ﬁrst explicit attempt to model delirium in rodents
administered the muscarinic receptor antagonist atropine
intraperitoneally and demonstrated acute cognitive deﬁcits in
a blind alley maze and EEG slowing reminiscent of delirium
[21].More recently, investigations of the role of inﬂammatory
processes have involved mimicking severe sepsis using either
high doses of lipopolysaccharide (LPS; 5–10 mg/kg), or by
performing caecal ligation and puncture leading to polymicro-
bial sepsis. Acute alpha activity slowing in EEG and decreased
glucose uptake has been demonstrated by microPET at 24 h
post-LPS [22]. LPS studies have focused on long-term impair-
ment, demonstrating neuronal death, synaptic loss and spatial
memory deﬁcits in rats at 12 weeks post-LPS (10 mg/kg). It is
of interest, but so far little studied, that GABAergic anaes-
thetics, frequently used in ICU patients, may increase mortality
in active infection-induced critical illness in rodents [23].
Furthermore, subthreshold scopolamine doses can produce
working memory dysfunction in rodents when combined
with diazepam [24]. IL-1β contributes to cognitive dysfunc-
tion during surgery, infection and sepsis [25, 26] and can dir-
ectly increase GABA receptor expression and GABAergic
tone [27]. Thus, interactions among IL-1β, GABA and ACh
are of considerable interest for delirium and require detailed
further study.
Recent models addressing inﬂammatory processes combine
much lower levels of systemic inﬂammation superimposed
upon prior brain vulnerability, more closely modelling delirium
caused by mild insults in older patients. In aged mice [28] or
those with pre-existing neurodegenerative pathology [29], low
doses of LPS induced acute and reversible cognitive dysfunc-
tion. Microglia primed by primary pathology to produce
exaggerated IL-1β responses to subsequent inﬂammatory
stimulation [30] were implicated in the acute cognitive deﬁcits
in both of these studies. Although the role of microglial
priming remains unproven, activated microglia robustly
expressed COX-1 and the described cognitive deﬁcits were de-
pendent on both COX-1-mediated prostaglandins and IL-1β
[31]. Animals with selective lesions of the basal forebrain cho-
linergic system have been demonstrated to be susceptible,
upon systemic LPS dosing (100 µg/kg), to acute cognitive dys-
function that was reversible upon inﬂammatory resolution
[32]. These deﬁcits were largely prevented by treatment with
the acetylcholinesterase inhibitor donepezil [32]. These data
suggest a role for acetylcholine on a background of neurode-
generative pathology in the cholinergic system. How systemic
inﬂammatory mediators and brain vulnerability might interact
during sickness behaviour syndrome to produce delirium has
been more comprehensively reviewed elsewhere [8].
Prevention
Prevention strategies are typically based on identifying high-
risk patients, and addressing modiﬁable risk factors in these
patients. In some settings, such as geriatrics wards, most
patients can be considered high risk. In settings with a wider
range of levels of vulnerability several delirium risk scales have
been validated, aimed at appropriate risk stratiﬁcation and re-
source allocation. These include scales developed for the
Intensive Care Unit (ICU) (PRE-DELIRIC [33]), cardiothoracic
[34] and vascular surgery units [35]. Several overlapping delirium
prevention programmes focused on non-pharmacological
measures have been tested [2, 36–40] and generally they have
been found to be cost-effective [41]. Delirium prevention by
the use of speciﬁc drugs shows some promise [42] although
these studies have been restricted to surgical patients [43].
Currently, pending a stronger body of positive evidence,
pharmacological prevention is not advocated in routine clin-
ical practice. Future deﬁnitive studies will likely be large and
complex, because of the many difﬁculties involved in study
design. For example, in existing randomised controlled trials
of pharmacological prevention, the heterogeneity of the clin-
ically managed control arms limits study comparability.
Measurement of effect in drug studies also requires care
because most delirium scales are biased towards hyperactive
symptoms; thus the sedation caused by antipsychotic drugs
may improve the overall scale score while leaving any positive
or negative effects on hypoactive symptoms inadequately
assessed. Conversely, some commentators have noted that
the effect of antipsychotics is independent of sedative activity
and temporally inconsistent with the antipsychotic effect
observed in functional psychoses, thus pointing towards
more direct actions in preventing or treating the syndrome of
delirium [44].
Future research on delirium prevention should address
several issues. It is still unclear if interventions are more efﬁ-
cacious in higher risk patients. Related to this, tailored delirium
prevention as advocated by the NICE guidelines [2] requires
further detailed evaluation. It is plausible that some highly vul-
nerable patients could beneﬁt from more resource-intensive tai-
lored prevention packages; stratiﬁcation of risk would make
realisation of such interventions in clinical practice more feas-
ible. More broadly, it is important to clarify if prevention and
treatment are meaningfully distinct approaches, because inci-
dent and prevalent delirium may overlap in prodromal or sub-
syndromal forms. Another unresolved problem is how to
translate existing research ﬁndings into routine care. Studies
that consider low cost, practical implementation in mainstream
healthcare are still lacking. However, some elements of multi-
component programmes are easier and cheaper to implement
than others, and healthcare providers should consider introdu-
cing these components into practice now, rather than adopting
an all-or-none approach for a particular package of measures.
For example, urging staff to provide hearing aids and glasses,
involving family members in care, providing frequent orien-
tation, ensuring adequate hydration and nutrition, detecting
and treating pain and constipation, avoiding urinary catheter-
isation, and avoiding deliriogenic drugs, are readily achievable
in many settings without additional stafﬁng. Other elements,
such as cognitive stimulation, may be more difﬁcult and costly
to implement.
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Assessment
Under-detection of delirium is well documented: at least
two-thirds of cases are missed [45, 46]. Older age, the pres-
ence of comorbid neuropsychiatric disorders, prominent
pain and hypoactive presentation contribute to decreased
recognition. Diagnosis etection is also hindered by confusing
nomenclature, with many terms describing acute brain dis-
turbance in use in different populations and treatment set-
tings. The use of ‘delirium’ as an umbrella term is important
in engaging and educating colleagues throughout the health-
care spectrum. A second barrier to delirium assessment is
the wide variety of detection tools available. This reﬂects the
clinical heterogeneity of the condition and the varying skills
of assessors with identiﬁcation of some delirium through
observed behaviours, and in other cases by detailed cognitive
assessment requiring more expertise [47].While the agitated
patient is easily identiﬁed, the more common presentation
of hypoactive delirium is frequently missed. For this reason,
regular mental status assessment needs to become a ‘vital
sign’ embedded into basic hospital care. One important
advance in the UK is the adoption of a new National Early
Warning Score, which incorporates a 4-point level of con-
sciousness measure [48]. Some recent evidence suggests
that the reduced level of consciousness is a speciﬁc (though
not sensitive) sign of delirium [49, 50], and so it could
become a stimulus for speciﬁc delirium screening, bolster-
ing rates of detection. These and other and system-wide
approaches, embedded into routine practice, are likely
required to address the huge unmet need for delirium as-
sessment [51].
Whatever triggers are used, further assessment can be
made using a validated tool, such as the 4 “A”s Test (4AT;
Bellelli et al., submitted), the Confusion Assessment Method
or its variants [52, 53], the Nursing Delirium Screening Scale
[54] or others. Selection of the tool depends on multiple
factors, including the time available, the level of tester skill,
and the clinical setting. In most general hospital environments,
the most successful assessment tools are likely to be simple,
quick and usable without extensive training in delirium.
Lessons could be learnt from the Netherlands, where the
Delirium Observation Screening scale [55] has been implemen-
ted in <50% of hospitals. Assessment tools that discriminate
between delirium and related neuropsychiatric conditions, es-
pecially dementia or depression are important, yet the ability of
commonly used screening tools to achieve this is poorly
studied [56].
Specialist delirium assessment tools and investigations
may be appropriate in a minority of patients with delirium
where the precipitant is unclear or the clinical course unusual.
The Memorial Delirium Assessment Scale [57], Delirium
Rating Scale–Revised–98 [58] and Cognitive Test for Delirium
[59] enable detailed assessment to detect delirium in cases in-
volving related neuropsychiatric conditions. Future develop-
ments in objective assessment of attention [60], and more
detailed assessment of the level of consciousness [49]may assist
delirium detection. EEG may show moderate to severe
generalised slowing of brain activity in delirium, distinguishing
the condition from dementia [61] and may also detect non-
convulsive status epilepticus.
Neuroimaging is routinely used in clinical practice to ex-
clude primary neurological causes of delirium such as stroke,
haemorrhage and tumours. Yet the evidence base informing
decisions on neuroimaging in delirium is very small; a recent
review of the literature found only 16 studies with just 350
patients with documented delirium scanned in total [62].
This is surprising given that in some centres 50% or more of
patients with delirium undergo CT scanning. This matters
not only because of possibly inappropriate use of resources,
but also because CT scanning may be stressful for some
patients. Future research has a role in clarifying the beneﬁts
of CT scanning in clinical practice [63]. Additionally, MRI or
other modalities could shed light on predisposing factors,
neural substrates of delirium and consequences of delirium.
Lumbar puncture currently only has a clinical role in exclud-
ing speciﬁc CNS causes of delirium. Research may yield
useful biomarkers of CNS inﬂammation or damage that
could be used in future clinical practice [14].
Management
Guidance on the management of delirium is ubiquitous in
general medical and geriatrics textbooks as well as in delirium
review articles. Yet proving the effectiveness of delirium
treatment has been surprisingly difﬁcult, and there is little
direct positive evidence available. For example, a recent large
RCT showed signiﬁcant effects on patient and care experi-
ence, but not on mortality, length of stay and other outcomes
[64]. Because of the lack of evidence, recommendations on
management have come from expert consensus. There is
broad agreement with respect to most aspects of care [2, 65],
including: treating all the probable acute causes; reducing the
impact of predisposing factors (such as sensory impair-
ments); optimising physiological conditions for the brain
(e.g. providing adequate oxygen delivery and stopping or re-
ducing deliriogenic drugs); treating the syndrome itself,
through providing a stable and reassuring environment and
sometimes using drugs for agitation and distress (see below);
avoiding complications such as aspiration pneumonia and
prolonged immobility; providing rehabilitation; and commu-
nicating effectively with families. Future research might
involve structured programmes of intensive intervention
along these lines, though deciding which treatment arm com-
ponents are not offered to patients randomised to usual care
raises complicated ethical and scientiﬁc challenges.
The evidence base on pharmacological intervention in de-
lirium is slight. Small randomised controlled trials of quetia-
pine in medical and ICU patients suggest a positive effect, but
more robust studies are required [66, 67]. Conventional man-
agement often involves low dose haloperidol, though this
reﬂects tradition rather than the availability of positive studies.
There is currently little evidence in favour or against the use of
newer antipsychotics, but a study of risperidone in
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subsyndromal delirium shows some promise [68, 69]. Many
practitioners already use risperidone and other newer antipsy-
chotics, however [65]. In current practice, consideration of
efﬁcacy (and principal modes of action) versus signiﬁcant risk
of adverse effects in often frail elderly patients, means that
antipsychotics are used mainly where non-pharmacological
methods have failed to control distressing psychotic or other
neuropsychiatric symptoms or the safety of the patient or
others is compromised. The optimal duration of such treat-
ment is uncertain, but short-term exposure with treatment dis-
continuation soon after symptoms settle is preferred [44, 70].
However, evidence of post-delirium recall suggests psychotic
phenomena may warrant more aggressive treatment, even
among hypoactive patients [71]. This is more controversial, as
antipsychotic medications used to treat mild agitation may
promote hypoactive delirium. Additional studies are required,
perhaps targeted to components of the delirium syndrome,
such as psychosis [42, 72].
High quality delirium care is complex and time-consuming,
and in all but the mildest and briefest cases requires specialist
expertise. For some patients, management may be best de-
livered in specialist ‘delirium rooms’ providing integrated
medical and psychiatric care in an optimised, secured environ-
ment. In addition to the theoretical advantages, evidence indi-
cates that such approaches reduce the length of delirium
and increase the likelihood of recovery to independent
living [73]. Some of these beneﬁts are achieved by special-
ist geriatric care units, which have a wider remit for
function-focused care [74] but given the high prevalence
of delirium within hospitals these are only available to a pro-
portion of delirium sufferers. Therefore, although specialist
delirium units may have a role in complex cases, ensuring
better whole-hospital care is also necessary. Some sugges-
tions regarding the features of a ‘Delirium-Friendly Hospital’
are provided in Box 1.
Features of a Delirium-Friendly Hospital
• Staff aware that delirium affects 1 in 8 of their patients
• Staff all have basic knowledge of delirium
• Delirium screening is routine
• Delirium information for patients and families is available
• The hospital has a delirium pathway
• Basic delirium prevention measures are in place
• Environment: orientation information, signage, etc.
• Awareness of value of role of family/carers
• Availability of expert specialist care
The management of delirium should include strong con-
sideration of post-discharge follow-up, given the frequency
of persistent delirium at discharge and strong association
with future dementia risk [4, 75]. This is a neglected area of
delirium care, given that studies have shown how many
patients’ understanding of the episode can be coloured by
feelings of embarrassment or worries that they were ‘senile’ or
‘mad’ [76]. Moreover, post-delirium recall can produce a con-
dition similar to post-traumatic stress disorder, requiring psy-
chological support [71, 77]. Another research and practice
priority is to understand why some episodes of delirium are so
persistent and who is at a greater risk of this and of post-
delirium cognitive decline, either through risk stratiﬁcation or
biomarker development. Early identiﬁcation of such patient
will help to focus treatment and in offering prognostic infor-
mation for patients and families.
Future directions
Delirium poses considerable challenges in multiple domains
of science and healthcare. Much remains to be discovered.
Yet clinical implementation of prevention, detection and
treatment strategies is a clear imperative, for the following
reasons: (i) research has shown that delirium prevention is ef-
fective; (ii) detection of established delirium is essential to
relieve distress [78] and improve communication with families;
(iii) though speciﬁc delirium treatment is not well supported
by formal studies, clinical experience strongly suggests that
identifying and treating causes and providing comprehensive
supportive care is efﬁcacious.
The research priorities are broad [72, 79, 80]. Recent animal
model research has suggested possible mechanisms [18], and
even treatment strategies. Increased capacity for animal model
research is urgently required. Understanding the relationship
between delirium and dementia is a primary target for mech-
anistic research, given the potential for primary or secondary
prevention of dementia and with many important questions
outstanding, such as the effects of delirium severity, duration,
and presumed aetiology as modiﬁers of the relationship.
Although several instruments for delirium assessment are
already available in research and practice, further work could
focus on the development of objective cognitive tests and
more detailed assessments of the level of consciousness. The
beneﬁts would include more ﬁnely grained measures for clin-
ical trials, and more precise assessment of the effects of treat-
ments on subcomponents of delirium. Positive evidence in
favour of delirium treatment programmes would powerfully
stimulate efforts to improve routine care; to some extent this
is now being observed as a positive consequence of the solid
evidence supporting delirium prevention.
Conclusions
Delirium is one of the major unmet medical needs in modern
clinical practice. Understanding of the characteristics, causes and
consequences of delirium has grown considerably in recent
decades. Advances in knowledge of mechanisms, treatment and
implementation of prevention and detection strategies are current
priorities. The expanding base of interest among researchers, clin-
icians and policymakers evident in recent years give rise for cau-
tious optimism that there will be progress on these fronts.
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Key points
• Delirium is one of the major unmet medical needs in
modern clinical practice.
• Delirium strongly predicts future new-onset dementia and
accelerates existing dementia.
• Delirium prevention is effective but implementation in clin-
ical practice is still lacking.
• Animal model research has provided valuable insights into
possible mechanisms.
• Higher detection rates of delirium in routine practice
remains a major priority.
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